BBA
CRVS icon

Baader Bank Aktiengesellschaft’s Corvus Pharmaceuticals CRVS Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-24,911
Closed -$17.7K – 433
2023
Q1 		$17.7K Buy
+24,911
New +$19.4K ﹤0.01% 345

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Baader Bank Aktiengesellschaft's CRVS Position: Q2 2023 in Review

Baader Bank Aktiengesellschaft sold out of Corvus Pharmaceuticals (CRVS) in Q2 2023, closing a stake of 24,911 shares — an estimated $17.7K sold.

Baader Bank Aktiengesellschaft first reported a position in CRVS in Q1 2023 and held it in 1 quarter. The position peaked at $17.7K in Q1 2023. 52 funds tracked by Wall St. Rank hold CRVS as of Q2 2023.

  • Baader Bank Aktiengesellschaft reported no remaining Corvus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 24,911 Corvus Pharmaceuticals shares in Q2 2023, an estimated $17.7K.
  • Baader Bank Aktiengesellschaft first reported a position in Corvus Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Baader Bank Aktiengesellschaft's Corvus Pharmaceuticals position peaked at $17.7K in Q1 2023.
  • 52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2023.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q2 2023, filed 11 Aug 2023.